Abstracts tagged "biomarkers and disease-modifying antirheumatic drugs"

Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Adrian Levitsky¹, Malin Erlandsson², Maria Bokarewa² and Ronald F. van Vollenhoven³, ¹The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
Abstract Number: 1790 • 2013 ACR/ARHP Annual Meeting
Serum Amyloid A Levels Model Rheumatoid Arthritis Disease Activity Better Than C-Reactive Protein Levels Especially During Treatment With Anti-Tumor Necrosis Factor α Therapy (Etanercept)
Ilinca D. Metes¹, Douglas W. Chew², Aarat M. Patel¹, G.K. Balasubramani³, Jeffrey R. Curtis⁴, S. Louis Bridges Jr.⁵, Stephen R. Wisniewski⁶, Larry W. Moreland⁷ and Marc C. Levesque⁸, ¹Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: C reactive protein (CRP) levels have been used extensively to model disease activity in rheumatoid arthritis (RA). However, TNF antagonist therapy (and likely therapy…
Abstract Number: 1473 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects
Ilinca D. Metes¹, Douglas W. Chew¹, Aarat M. Patel¹, G.K. Balasubramani², S. Louis Bridges Jr.³, Jeffrey R. Curtis⁴, Stephen R. Wisniewski², Larry W. Moreland⁵ and Marc C. Levesque⁶, ¹Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Amyloidosis is often due to an underlying inflammatory disorder, such as rheumatoid arthritis (RA), with organ deposition of serum amyloid A (SAA). Oral disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].